02:23 PM EDT, 09/10/2024 (MT Newswires) -- Altimmune ( ALT ) shares were up nearly 10% in recent Tuesday trading after the company said pemvidutide resulted in a lean loss ratio of 21.9% in a sub-study of a phase 2 Momentum obesity trial.

The company said lean mass preservation for subjects aged 60 and older at week 48 was greater and their change in lean mass compared to total mass was 19.9%.

Altimmune ( ALT ) is developing pemvidutide for the treatment of obesity and metabolic dysfunction-associated steatohepatitis, according to the company.

Price: 7.00, Change: +0.62, Percent Change: +9.72